Paper Details

  1. Home
  2. Paper Details

Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.

Author: GastlGuenther, GisslingerHeinz, JedrzejczakWieslaw-Wiktor, LinWerner, PytlikRobert, SchlöglErnst, SteurerMichael

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Anagrelide effectively controlled platelet counts in thrombocytosis associated with myeloproliferative disorders, offering potential benefit in managing thromboembolic complications.
Paper Details　
Original Abstract of the Article :
Although the platelet count does not correlate with the rate of thrombosis, there is evidence that a strict control of the platelet count decreases the incidence of thromboembolic complications in essential thrombocythemia. In the current study, the authors evaluated the efficacy and tolerability of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.20646

データ提供：米国国立医学図書館（NLM）

Anagrelide: A Potential Oasis for Thrombocytosis in Myeloproliferative Disorders

The management of [thrombocytosis] associated with [myeloproliferative disorders] is a complex and critical task. This study investigates the efficacy and safety of [anagrelide] as a treatment option for this condition. It's like searching for a safe and effective solution in the vast and sometimes treacherous desert of [hematologic disorders].

Anagrelide: A Promising Treatment for Thrombocytosis

The study found that [anagrelide] was effective in reducing [platelet count] in patients with [thrombocytosis] associated with [myeloproliferative disorders]. It also demonstrated a favorable safety profile. It's like finding a cool and refreshing spring in the midst of a hot and dusty desert. This study offers a potential new path for managing this challenging condition.

Navigating Thrombocytosis: A Journey of Careful Management

While [anagrelide] appears to be a promising treatment option, it's important to remember that managing [thrombocytosis] requires a careful and personalized approach. Regular monitoring and close collaboration with your doctor are essential. It's like navigating a desert, being aware of potential challenges and having the right tools and resources to overcome them.

Dr. Camel's Conclusion

This study offers a ray of hope for those struggling with [thrombocytosis] associated with [myeloproliferative disorders]. It's a reminder that even in the vast and often challenging desert of [hematology], there are oases of innovation and progress to be found. Let's continue to explore new treatment options and find the best paths to better health for those affected by this condition.

Date :
  1. Date Completed 2004-12-22
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

15476273

DOI: Digital Object Identifier

10.1002/cncr.20646

Related Literature

Article Analysis
・Side Effects of anagrelide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.